The active stages of intestinal inflammation and the pathogenesis of ulcerative colitis are
associated with superficial mucosal damage and intermittent wounding that leads to
epithelial barrier defects and increased permeability. The standard therapeutic interventions
for colitis have focused mainly on maintaining the remission levels of the disease.
Nonetheless, such treatment strategies (using anti‐inflammatory, immunomodulatory
agents) do not address colitis' root cause, especially the mucosal damage and dysregulated …

In article number 2103189, Yury Rochev, Abhay Pandit, and co-workers develop a biphasic
HMW-hyaluronan (HA) enema suspension that protects the dysregulated colitis colon
epithelium. The developed HA-based system modulate the intestinal epithelial junctional
proteins and regulatory signalling pathways, resulting in attenuation of inflammation and
mucosal protection. Furthermore, the developed system helps restore the dysregulated
intestinal barrier functions and helps in distal colitis management.